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Travel time is a barrier to
radiation therapy (RT) access
and use. This study quanti-
fied the rate at which RT use
decreased with travel time,
its variation across cancer
sites, and how it changed
with opening new centers.
Such findings can be incor-
porated into strategic plan-
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http://dx.doi.org/10.1016/j.ijrobp.2015.06.004Purpose: To model and quantify the relationship between radiation therapy (RT) use
and travel time to RT services.
Methods and Materials: Population-based registries and databases were used to iden-
tify both incident cancer patient and patients receiving RT within 1 year of diagnosis
(RT1y) in British Columbia, Canada, between 1992 and 2011. The effects of age,
gender, diagnosis year, income, prevailing wait time, and travel duration for RT on
RT1y were assessed. Significant factors from univariate analyses were included in a
multivariable logistic regression model. The shape of the travel timeeRT1y curve
was represented by generalized additive and segmented regression models. Analyses
were conducted for breast, lung, and genitourinary cancer separately and for all cancer
sites combined.
Results: After adjustment for age, gender, diagnosis year, income, and prevailing wait
times, increasing travel time to the closest RT facility had a negative impact RT1y. The
shape of the travel timeeRT1y curve varied with cancer type. For breast cancer, the
odds of RT1y were constant for the first 2 driving hours and decreased at 17% per hour
thereafter. For lung cancer, the odds of RT1y decreased by 16% after 20 minutes and
then decreased at 6% per hour. Genitourinary cancer RT1y was relatively independent
of travel time. For all cancer sites combined, the odds of RT1y were constant within
the first 2 driving hours and decreased at 7% per hour thereafter.
Conclusions: Travel time to receive RT has a different impact on RT1y for different tu-
mor sites. The results provide evidence-based insights for the configuration of catchmentBritish Columbia Cancer
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Successful strategic planning for radiation therapy (RT)
services would distribute RT facilities geographically in a
way that optimizes access while minimizing capital infra-
structure investment (1). Historically, RT facilities have
been located together with general hospital facilities in
larger population centers. However, facility centralization
may result in long travel times and underuse of RT (2). The
problem is especially prominent in countries with a pub-
licly funded and planned health system and population
spread over a large geographic area, such as in Australia
and Canada (2-4).
Long travel distance (or time) has been associated with
lower RT use (5-12). Long travel distances to RT facilities
have been associated with a greater chance of mastectomy
for breast cancer (5, 7); lower odds of RT use among pa-
tients with colon, rectum, lung, ovary, and prostate cancer
(10); and less frequent use of palliative radiation therapy (6,
9, 12). Some studies use a straight-line distance or an
approximate distance as a proxy for traveling inconve-
nience (5, 8). Most previous studies have stratified patients
by certain cutoff points of travel distance/time (eg 10 miles
or 2 hours) and have compared RT use between dichoto-
mized distance groups (5-7). The choice of cutoff points is
usually arbitrary. Little work has been done to validate
travel distance (time) cutoff points or describe use by
cancer site, age, or other factors. It is also not known how
rapidly RT use changes after a new RT center is built in a
region that previously had inadequate geographic access, or
whether it varies by region or cancer site.
The purpose of this study was to determine how travel
time and the expansion of RT facilities influenced RT use in
British Columbia, Canada, over the past 20 years. In
particular, we investigated whether there is a time/travel
distance point after which RT use drops significantly for
breast, lung, and genitourinary cancer and for all 15 cancer
sites combined. One of our goals is to provide evidence-
based rationale to the geographic localization of RT ser-
vices to efficiently optimize RT use.Methods and Materials
Setting
British Columbia (BC), Canada, the geographic area of
study, has a land area of 922,509 km2 (356,181 sq mi). It is
densely populated in the lower mainland and more sparsely
populated in the northern and interior regions. In BC, all RT
is provided by the BC Cancer Agency through regional
cancer centers. The number of regional cancer centersincreased from 2 in 1992 to 5 in 2011 to serve a population
of 4.4 million (13), and the number of megavoltage radia-
tion therapy machines increased from 11 to 30 over this
same time period (for a timeline of major RT capacity in-
creases, see Appendix A, Table e1; available at www.
redjournal.org). Figure 1 shows the location and year
opened for the 5 cancer centers providing RT in BC in 2011.
Population and RT use
Residence at diagnosis (postal code), tumor site, age,
gender, and diagnosis date of all patients with incident
cases of invasive cancer and in situ breast cancer cases
diagnosed in BC from 1992 to 2011 were extracted from
the Cancer Registry. A total of 418,637 patients were
identified. Patients with nonmelanoma skin cancer (9.9%)
and patients without a valid postal code (0.9%) were
excluded. Each incident patient was linked to the radiation
therapy treatment database to identify the initiation date for
all radiation treatments including brachytherapy. We
defined RT use by individual patients as a binary variable
indicating whether the patient was treated with RT within
1 year of diagnosis (RT1y). The RT use by a group of
patients was defined as the proportion of patients treated
with RT within 1 year of diagnosis (RT1y rate).
Travel time
Driving time from a patient’s residence at diagnosis to the
nearest cancer center (which changed over the period of
study as new centers were built) was calculated using
MapPoint software (Microsoft, Redmond, WA). Patients for
whom the nearest cancer center was in the neighboring
province of Alberta were excluded (3.8% of patients). In
general, patients residing in remote locations typically
travel once at the start of their treatment and stay close to
the cancer center (in cancer-lodge or rental accommoda-
tions) for the duration of treatment rather than driving from
their homes for each appointment (1). To eliminate the
impact of extreme travel distances, patients who lived 10 or
more driving hours from the closest cancer center were also
excluded (1.1% of patients). Altogether, 352,989 incident
patients from 1992 to 2011 were included in the analysis.
Statistical analysis
Multiple logistic regression (MLR) (14), generalized addi-
tive (GA) (15), and segmented regression (SR) (16) models
were used. An MLR model was used to investigate the
association between various factors and RT1y. A GA model
was used to determine the functional relationship between
Fig. 1. Location and opening year of each cancer center in BC by 2011.
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characterize/parameterize this relationship.
In the MLR model, the dependent variable was RT1y.
Covariates included age at diagnosis, gender, diagnosis
year, prevailing wait time, average household income
level, and travel time in hours (3, 17-19). The prevailing
wait time for each patient was defined as the median wait
time from diagnosis to RT observed in other residents with
the same tumor site from the same health service delivery
areas (HSDA) (20) in the preceding 6 months (21). Each
patient’s residing local health area (LHA) (20) was cate-
gorized into 1 of 4 income levels based on the 25th, 50th,
and 75th percentile of the average household income of
each LHA.
A GA model was used to investigate the relationship
between travel time and RT1y. A plot of the fitted GA
model function graphically represents the relationship be-
tween RT1y and travel time adjusted for other variables
(see Appendix B for analytic details).
An SR model was used to determine whether the odds of
RT1y changed beyond specific travel time breakpoints.
This type of model allows for a piecewise linear relation-
ship with 2 segments of different slopes. The possibility of
2 breakpoints was also explored. The Bayesian information
criterion (BIC) (22) was used to compare the models used.
Models with lower BIC values are preferred.The 1998 opening of a cancer center in the interior of
BC greatly reduced the travel time for the surrounding
population. The impact of opening a new cancer center was
investigated by comparing RT1y rates over time for patients
living within a 2-hour drive from the eventual new center
with those for patients living within a 2-hour drive from 2
centers that were operating before 1992.
All analyses were conducted for each of the 3 cancer
sites that were responsible for the majority of RT use
(breast, lung, and genitourinary cancers) and for all 15
cancer sites combined. All analyses were carried out with
the statistical program R (R Core Team, 2013) and its add-
on libraries mgcv (15), segmented (23), and ggplot2.Results
Historical RT use
Within the 352,989 incident patients under study, 108,880
patients (30.8%) received a course of RTwithin 1 year from
diagnosis. Overall, the median driving time to the closest
cancer center was 24 minutes. In 1992, 76% of patients with
incident cases livedwithin a 2-hour drive to an RT facility; in
2011, 83% lived within a 2-hour drive to an RT facility. The
median average household income of all LHAs in 2001 was
Table 1 RT1y rate, including 95% confidence intervals, by age, gender, average household income level, prevailing wait time, travel
time, and diagnosis year
Factor
All 15 sites Breast Lung Genitourinary
Incident
cases RT1y rate (%)
Incident
cases RT1y rate (%)
Incident
cases RT1y rate (%)
Incident
cases RT1y rate (%)
Age (y)
<40 19,316 31.0 (30.4 to 31.7) 3150 65.5 (63.8 to 67.1) 410 49.3 (44.3 to 54.2) 1995 19.2 (17.4 to 21.0)
40-50 31,838 41.0 (40.5 to 41.6) 10,905 62.9 (62.0 to 63.8) 2384 59.3 (57.3 to 61.3) 2424 16.6 (15.1 to 18.1)
50-60 59,581 37.5 (37.1 to 37.9) 13,027 62.7 (61.8 to 63.5) 7138 55.0 (53.9 to 56.2) 10,489 22.3 (21.5 to 23.1)
60-70 90,314 34.1 (33.7 to 34.4) 12,919 56.7 (55.8 to 57.6) 13,926 48.2 (47.4 to 49.1) 23,679 29.9 (29.3 to 30.5)
70-80 95,982 29.4 (29.1 to 29.7) 10,897 44.7 (43.8 to 45.6) 16,667 41.2 (40.5 to 42.0) 23,194 34.7 (34.1 to 35.3)




27,412 28.0 (27.5 to 28.5) 3687 46.2 (44.6 to 47.9) 4622 41.1 (39.7 to 42.5) 5666 25.4 (24.2 to 26.5)
Second
quartile
64,779 30.3 (29.9 to 30.7) 9534 51.6 (50.6 to 52.6) 9584 43.5 (42.5 to 44.5) 14,135 27.0 (26.3 to 27.8)
Third
quartile
119,427 31.1 (30.8 to 31.3) 19,074 52.7 (52.0 to 53.4) 16,726 45.5 (44.8 to 46.3) 23,407 27.2 (26.7 to 27.8)
Highest
quartile
141,371 31.5 (31.2 to 31.7) 24,325 56.3 (55.7 to 57.0) 17,774 43.5 (42.8 to 44.2) 29,407 27.1 (26.6 to 27.6)
Gender
Female 172,191 33.3 (33.1 to 33.6) 56,263 53.8 (53.3 to 54.2) 22,119 43.4 (42.7 to 44.0) 5171 14.2 (13.2 to 15.1)
Male 180,798 28.5 (28.3 to 28.7) 357 36.7 (31.6 to 41.8) 26,587 44.5 (43.9 to 45.1) 67,444 28.0 (27.6 to 28.3)
Travel time
0-2 h 286,142 31.5 (31.3 to 31.7) 46,849 55.3 (54.8 to 55.8) 38,615 44.8 (44.3 to 45.3) 57,614 27.4 (27.0 to 27.8)
0-10 min 61,871 31.4 (31.1 to 31.8) 9935 55.1 (54.1 to 56.1) 8402 46.9 (45.8 to 48.0) 11,619 25.2 (24.4 to 26.0)
10-20 min 79,202 31.9 (31.6 to 32.2) 13,581 56.1 (55.3 to 57.0) 10,279 46.4 (45.4 to 47.4) 15,672 27.0 (26.3 to 27.7)
20-30 min 61,323 31.4 (31.0 to 31.8) 10,825 57.2 (56.3 to 58.1) 7747 42.8 (41.7 to 43.9) 12,336 27.1 (26.3 to 27.9)
30-40 min 21,256 31.7 (31.1 to 32.3) 3347 54.5 (52.8 to 56.2) 2868 42.8 (41.0 to 44.6) 4457 30.0 (28.6 to 31.4)
40-50 min 10,472 32.8 (31.9 to 33.8) 1594 55.2 (52.7 to 57.7) 1473 43.9 (41.3 to 46.5) 2303 32.6 (30.7 to 34.5)
50-60 min 12,393 29.9 (29.1 to 30.7) 1788 51.0 (48.6 to 53.3) 1880 42.9 (40.6 to 45.2) 2747 28.6 (26.9 to 30.3)
60-70 min 10,531 30.7 (29.8 to 31.5) 1543 52.3 (49.8 to 54.8) 1608 42.7 (40.3 to 45.1) 2211 28.5 (26.6 to 30.4)
70-80 min 4852 31.0 (29.7 to 32.3) 656 52.3 (48.4 to 56.2) 738 43.4 (39.8 to 47.0) 1069 27.6 (24.9 to 30.3)
80-90 min 4345 30.9 (29.5 to 32.3) 634 51.1 (47.1 to 55.1) 632 45.7 (41.7 to 49.7) 953 30.7 (27.7 to 33.7)
90-
100 min
8022 30.5 (29.5 to 31.5) 1171 50.5 (47.6 to 53.4) 1281 42.1 (39.4 to 44.8) 1685 28.0 (25.8 to 30.2)
100-
110 min
8209 30.3 (29.3 to 31.3) 1191 52.3 (49.4 to 55.2) 1190 43.2 (40.3 to 46.1) 1732 27.9 (25.8 to 30.0)
110-
120 min
3666 33.4 (31.9 to 35.0) 584 56.0 (51.9 to 60.1) 517 52.2 (47.8 to 56.6) 830 29.6 (26.4 to 32.8)
2-4 h 38,465 30.2 (29.7 to 30.7) 5581 52.1 (50.8 to 53.4) 5821 43.4 (42.1 to 44.7) 8647 26.2 (25.3 to 27.1)
4-6 h 19,451 25.3 (24.7 to 25.9) 2860 37.0 (35.2 to 38.8) 2813 38.0 (36.2 to 39.8) 4463 24.0 (22.7 to 25.3)
6-8 h 7443 25.6 (24.6 to 26.6) 1106 36.2 (33.3 to 39.1) 1246 35.7 (33.0 to 38.4) 1574 24.1 (22.0 to 26.2)




84,306 35.1 (34.8 to 35.5) 14,018 48.9 (48.1 to 49.7) 12,256 45.6 (44.7 to 46.5) 17,732 26.5 (25.9 to 27.2)
Second
quartile
84,277 24.5 (24.2 to 24.8) 13,793 56.2 (55.3 to 57.0) 12,124 44.6 (43.7 to 45.5) 17,851 26.5 (25.9 to 27.2)
Third
quartile
84,580 33.1 (32.8 to 33.4) 13,878 55.0 (54.1 to 55.8) 11,440 44.2 (43.3 to 45.1) 17,746 26.9 (26.2 to 27.6)
Longest
quartile
84,038 33.0 (32.6 to 33.3) 13,829 55.5 (54.6 to 56.3) 11,802 41.8 (40.9 to 42.7) 17,602 27.7 (27.1 to 28.4)
Diagnosis year
1992-1996 71,495 29.3 (29.0 to 29.6) 10,927 45.4 (44.4 to 46.3) 10,355 39.8 (38.8 to 40.7) 15,570 27.3 (26.6 to 28.0)
1997-2001 83,633 31.2 (30.9 to 31.6) 13,826 53.3 (52.4 to 54.1) 11,515 45.5 (44.6 to 46.5) 17,500 27.2 (26.6 to 27.9)
2002-2006 92,062 31.9 (31.5 to 32.2) 14,741 56.4 (55.6 to 57.2) 12,857 46.1 (45.3 to 47.0) 18,165 27.4 (26.8 to 28.1)
2007-2011 105,799 30.7 (30.4 to 31.0) 17,126 56.9 (56.1 to 57.6) 13,979 43.7 (42.9 to 44.6) 21,380 26.1 (25.5 to 26.7)
Total 352,989 30.8 (30.7 to 31.0) 56,602 53.6 (53.2 to 54.1) 48,706 44.0 (43.5 to 44.4) 72,615 27.0 (26.7 to 27.3)
Abbreviations: RT Z radiation therapy; RT1y rate Z proportion of incident cases in a group treated by RT within 1 year of diagnosis.
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median prevailing wait time (from diagnosis date to RT start
date) was 89 days. Table 1 shows the number of patients and
the RT1y rates with 95% confidence intervals grouped by
tumor site, gender, age at diagnosis, average household in-
come level, travel time, prevailing wait time, and diagnosis
year. RT1y rate was rather stable within the first 2 driving
hours and decreased as travel time increased. Patients living
within the nearest travel time quartile had RT1y rates of
31.7%, 55.4%, 47.6%, and 25.7% compared with 28.8%,
47.6%, 41.5%, and 25.4% for those living within the farthest
travel time quartile for all 15 cancer sites combined and for
breast, lung, and genitourinary cancers, respectively
(P<.0001). The overall RT1y rate among all 15 sites was
significantly higher after 1996 compared with before 1996.Factors associated with RT use
Table 2 shows the association between RT1y and several
patient characteristics under a multivariable logistic regres-
sion analysis. Longer driving time was significantly associ-
ated with lower odds of RT1y for all cancer sites under study.
With each additional driving hour to the closest RT facility,
the odds of RT1y for patients with breast, lung, and genito-
urinary cancer decreased by 11%, 7%, and 3%, respectively.
Age was negatively associated with the odds of RT1y for
breast or lung cancer. After adjustment for all other variables,
each additional 30 days of prevailing wait time reduced the
odds of RT1y by 5% and 11% for breast and lung cancer,
respectively. Higher average household income had a posi-
tive effect on RT1y, with the middle-income groups having
the highest RT1y rates, after adjustment for all otherTable 2 Multivariable logistic regression results for predictors of th
Factor
Odds ratios of receiving R
All 15 sites Brea
Travel time (h) 0.96* (0.95 to 0.96) 0.89* (0
Prevailing wait time (30 days) 1.00 (1.00 to 1.00) 0.95* (0
Gender
Female Reference Re
Male 0.83* (0.82 to 0.85) 0.59* (0
Average income level
Lowest quartile Reference Re
Second quartile 1.09* (1.05 to 1.12) 1.15* (1
Third quartile 1.04z (1.01 to 1.07) 1.01 (0
Highest quartile 1.01 (0.98 to 1.05) 1.08z (1
Age at diagnosis 0.98* (0.98 to 0.98) 0.96* (0
Diagnosis year
1992-1996 Reference Re
1997-2001 1.10* (1.07 to 1.12) 1.36* (1
2002-2006 1.13* (1.11 to 1.16) 1.57* (1
2006-2011 1.07* (1.05 to 1.10) 1.67* (1
Abbreviations: RT Z radiation therapy; RT1y Z RT within 1 year of diagn
* P<.01.
y P<.1.
z P<.05.variables. Compared with the first 5-year interval, the RT1y
in the most recent 5-year interval was significantly higher for
patients with breast and lung cancer, significantly lower for
patients with genitourinary cancer, and marginally increased
for all patients combined.
Smoothed relationship between RT use and travel
time
Figure 2 shows plots of the fitted GA model illustrating the
relationship between RT1y and driving time, after for all
other variables (reference levels: median value for contin-
uous variables, most frequency category for categorical
variables) were controlled for. The dashed lines indicate the
95% confidence intervals. Figure 2 demonstrates that RT use
was relatively consistent within a drive of approximately
2.5 hours to the closest RT facility and then decreased at
different rates dependent on the disease site. For patients with
breast cancer, there was a sharp decrease in RT1y beyond
2.5 hours. For lung cancer there was a persistent, nonlinear,
downward trend without a sharp breakpoint. For genitouri-
nary cancer, the relationship between RT1y and driving time
was rather flat. Relative to the RT1y level within a 2-hour
drive to the closest RT facility, the absolute decrease in the
RT1y rate with 5 to 6 hours of travel time was approximately
20%, 9%, and 3% for patients with breast, lung, and geni-
tourinary cancer respectively.
Estimated travel time breakpoints
Breakpoints in the relationship between travel time and
RT1y were observed for all sites under study. Table 3e binary variable RT1y
T within 1 year of diagnosis (95% confidence interval)
st cancer Lung cancer Genitourinary cancer
.88 to 0.90) 0.93* (0.92 to 0.94) 0.97* (0.96 to 0.98)
.93 to 0.98) 0.89* (0.84 to 0.94) 1.02* (1.01 to 1.03)
ference Reference Reference
.47 to 0.74) 1.09* (1.05 to 1.13) 2.37* (2.18 to 2.57)
ference Reference Reference
.06 to 1.24) 1.11* (1.03 to 1.19) 1.07y (1.00 to 1.15)
.94 to 1.10) 1.13* (1.05 to 1.21) 1.05 (0.98 to 1.13)
.00 to 1.17) 1.00 (0.94 to 1.08) 1.03 (0.96 to 1.11)
.96 to 0.97) 0.97* (0.96 to 0.97) 1.00 (1.00 to 1.00)
ference Reference Reference
.28 to 1.44) 1.23* (1.16 to 1.30) 0.97 (0.92 to 1.02)
.47 to 1.67) 1.30* (1.23 to 1.38) 0.97 (0.91 to 1.03)
.56 to 1.80) 1.21* (1.15 to 1.28) 0.90* (0.85 to 0.96)
osis.
Over Travel Time
Fig. 2. Radiation therapy within 1 year of diagnosis (RT1y) generalized additive model smoothed curve, including 95%
confidence intervals for travel time. The 3 vertical lines indicate the 25th, 50th, and 75th percentile of patients’ travel times.
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of each segment. The estimated breakpoint for breast
cancer was at 2.2 driving hours. The odds of RT1y
decreased at a relative rate of 17% per hour beyond
2.2 hours. For lung cancer, the estimated breakpoint was
around 22 minutes (0.4 hours) of driving. The odds of
RT1y decreased by 16% within the first 22 minutes and
further decreased at a relative rate of 6% per hour there-
after. Genitourinary cancer showed an upward RT use
trend before reaching the breakpoint at 0.6 hours. For all
15 sites combined, the estimated breakpoint was approx-
imately 2 hours.Table 3 Estimated breakpoints and segment slopes for the relations
Site
Estimated
breakpoint (h) (95% CI)
D
All 15 sites 2.0 (1.5 - 2.4)
Breast 2.2 (1.6 - 2.8)
Lung 0.4 (0.2 - 0.5)
Genitourinary 0.6 (0.4 - 0.7)
Abbreviations: CI Z confidence interval; RT1y Z radiation therapy withinModel comparison
We used 3 models (an MLR, a GA, and an SR) to describe
the relationship between RT1y and travel time, adjusting
for other variables. Each model had advantages. The MLR
model was the simplest, but it was the least accurate: as we
observed from the GA plots that the relationship between
RT1y and travel time was not necessarily linear. The GA
model was the most flexible approach in capturing the
shape of the relationship, but it was not generalizable
because of the lack of interpretability of its coefficients.
The SR was the most informative and useful model forhip between travel time and RT1y
riving time
interval (h)
% Change in odds
of RT1y per hour (95% CI)
0-2.0 2% (0% - 4%)
2.0-10 7% (8% - 6%)
0-2.2 2% (6% - 3%)
2.2-10 17% (19% - 14%)
0-0.4 38% (55% - 15%)
0.4-10 6% (7% - 5%)
0-0.6 61% (36% - 91%)
0.6-10 6% (7% - 4%)
1 year of diagnosis.
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if the relationship appears to be segmented.
On the basis of the corresponding BIC statistics, the SR
model is the best of the 3 models in describing the rela-
tionship between RT1y and travel time for breast cancer,
genitourinary cancer, and all 15 sites combined; MLR is
considered the best model for lung cancer.
Effect of opening a new center
The opening of a cancer center in Kelowna in 1998 pro-
vided new RT access within a 2-hour drive for the popu-
lation whose commute to a cancer center had previously
been over 4 hours. Other RT capacity increases in BC
during the time improved capacity but did not dramatically
change the proportion of patients within a 2-hour drive
from an RT facility. Figure 3 shows that the impact on
RT1y of opening the Kelowna center varied by tumor site.
RT1y rate for lung cancer reached provincial average levels
within a year and for genitourinary cancer eventually
exceeded the rates of the 2 reference centers. The gap in
RT1y rates for breast cancer narrowed with the opening of
the Kelowna center but remained lower than that observed
for patients living near the reference centers through 2011.Fig. 3. Comparison of radiation therapy within 1 year of dia
confidence intervals) between the new center and the 2 referencFor all 15 sites combined, RT1y for patients living within a
2-hour drive to the new center reached provincial levels by
the fifth year.Discussion
In this study, we graphically demonstrated and analytically
explored the relationships between RT1y and travel (driving)
times to the closest RT facility. RT1y of the 3 tumor sites under
study showed different patterns as travel time increased. Even
though RT1y decreased with travel time for all sites under
study, the 75th percentile of travel time for each site showed
that the majority of patients had rather similar RT access and
use, especially for breast and genitourinary cancer. Patients
who resided beyond the 75th percentile (farthest) of travel
time had the lowest RT1y (Fig. 2). Jones et al (10) came to a
similar conclusion for breast and prostate cancer patients
using data from North England.
Breakpoints in the relationship between travel time and
RT1y were detected for all sites under study. Breast cancer
was the only site showing a clear threshold that RT1y holds
constant until and decreases after. The likely reason is that
most breast cancer patients have the option of choosing2-hour DrivingFrom Within
gnosis (RT1y) rates within a 2-hour drive (including 95%
e centers.
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followed by radiation therapy. Inasmuch as mastectomy is
available in more locations than radiation therapy, some
patients may choose mastectomy over BCS with post-
operative RT to avoid the need to leave their home com-
munities for a course of RT that may take 3 to 6 weeks.
Variation in BCS rates by distance to an RT facility has
been observed by others (5, 11). Our study suggests that
2 hours may be the cut point for the decision between
mastectomy and BCS followed by RT. For most patients, a
daily 1-way commute for RT longer than 2 hours would
likely mean seeking accommodation near the RT center and
staying away from home for the duration of daily RT.
The analyses presented in this study do not support a
constant-then-decrease relationship for lung cancer. It ap-
pears that RT1y for lung cancer is relatively stable only
within the first 20 minutes of travel time, and it then de-
creases dramatically by a 30-minute commute with further
slight decreases with longer travel times thereafter. This
may be because more than 70% of RT for lung cancer is for
palliation, and longer travel may present greater challenges
for patients with poorer performance status.
We observed that RT1y is rather independent of travel
time for patients with genitourinary cancer. A possible
explanation is that the accessibility of the 2 main treatments
for localized prostate cancer (radical prostatectomy and
RT) is similar geographically in BC. Most urologists per-
forming radical prostatectomy were in larger metropolitan
areas; therefore, patients are less likely to choose either
over the other because of geographic barriers (for details on
brachytherapy utilization, see Appendix C, Figure e1;
available at www.redjournal.org).
The analyses and discussion above suggest hypotheses
that require further investigation. Besides the factors
included in this study, several other factors may have
influenced the observed relationship between RT1y and
travel time, such as stage of disease, regional practice
patterns and beliefs, and patients’ preferences. The impact
of these factors, not available in the current study, could be
examined in future research.
The GA and SR models have not been widely applied in
RT use analysis. Athas et al (7) used a GA model to visu-
alize the association between travel distance and RT use
after BCS, but those authors did not investigate whether
there was a travel distance breakpoint and the rate at which
use decreased beyond the breakpoint.
Understanding how geographic factors affect service use
at a population level can be important in location-allocation
decision making and strategic planning for the optimal
location of cancer centers. Our study, using data of the past
20 years in BC, suggests that locating RT facilities within a
2-hour drive from most patients would likely result in
similar RT use for curative-intent indications. However, RT
facilities would need to be located within a 20-minute drive
from most patients if optimization of RT use for palliative-
intent (represented by lung cancer) was a priority. This
study provides evidence-based inputs to RT locationoptimization and resource planning. Integrating the out-
comes of this study with location optimization models (1)
will allow system planners to investigate the locations of
RT facilities that maximize use for patients with different
types of cancer and the appropriate staffing level for each
facility.
Our study further suggests that the opening of an RT fa-
cility, especially in a previously underserved area, is associ-
ated with a substantial increase of RT use in the surrounding
area.A similar impact of systemexpansion onRTuse has been
described, but in less detail (3, 24). The opening of the cancer
center in the interior of BC in 1998 resulted in the overall
RT1y rate within a 2-hour drive to reach the level of the
reference centers within 5 years. The improvement in RT1y
rates started in 1997 because patients who received their di-
agnoses in late 1997 had access to the new center 1 year after
diagnosis. The increase in 1997 also results partially from the
fact that, before the center opened, radiation oncologists were
hired to see patients from these regions, which increased the
awareness and use of RT before the center actually started
treating patients. The rise in the use of breast RT predates the
opening of the center, and some of the rise over time likely
reflects provincial changes in the use of breast conservation
known to have occurred over that time. The later rise in RTuse
of genitourinary cancer in 2007 in the new center’s catchment
area reflects 3 things that happened between 2007 and 2010. A
prostate brachytherapy program was implemented in this re-
gion, new linear accelerator infrastructurewas added, and new
radiation oncologists were added. The use of prostate
brachytherapy is known to be highest in this region, likely
resulting in part to the collective belief system of the local
urologists and radiation oncologists. Other factors also have a
likely impact on the rate of change in use and the eventual
steady state of RT1y rate, such as stage distribution, age dis-
tribution, and patient preferences.
It is concluded that the rate at which RT use decreases
with travel time varies by cancer site, in terms of both the
point at which use begins to change and the rate of decrease
thereafter. Such findings can be incorporated into strategic
planning for the placement of RT facilities.References
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